Https://www.jkb.com.cn/ Liaoning Channel 01-16-2020
Original title :The new drug Carrimycin Produced by the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences Won National Awards and Received Global Attention
At noon on January 11, 2020, the China Top 10 Advancement Projects in Pharmaceutical Biotechnology in 2019 were officially announced. Carrimycin, jointly developed by the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Shenyang Tonglian Group, was selected as the China Top 10 Advancement Projects in Pharmaceutical Biotechnology in 2019 and Topped the list of online voting.
Academician Wei Yuquan (left) and Professor Wang Yiguang
It is reported that, as the top summit in domestic pharmaceutical field, this event is co-sponsored by the China Medicinal Biotechnology Association (CMBA) and the Chinese Medicinal Biotechnology, representing the highest level of pharmaceutical development in China. The event draws on attention from both domestic and foreign medical-related professional fields.
R&D of Carrimycin is led by Professor Wang Yiguang and it is the world’s first new drug with practical value successfully developed by using synthetic biology technology.
The R&D team led by Professor Wang Yiguang, after 30 years of painstaking research and clinical comparisons, found that Carrimycin not only has the characteristics featured by super antibiotics such as permeability, low adverse reaction rate, resistance to drug resistance, resistance to super bacteria, but also makes major breakthroughs in terms of anti-inflammatory immunity, intervention in tumor progression, and suppression of tumor metastasis.
At present, Carrimycin has been officially launched in China in October 2019.
As a new type of drug independently developed by China, Carrimycin has received high attention from the pharmaceutical research field in the United States and many other countries, and it is expected to become a pioneer of China’s primary drug going global. In the future, the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Shenyang Tonglian Group will continue to explore the infinite possibilities of Carrimycin in the field of disease prevention and treatment.
Source: Liaoning Correspondent Station China Daily